



GENMAB TO PRESENT AT THREE JUNE INVESTOR CONFERENCES

Summary: Genmab's management will present at three investor conferences in June.

Copenhagen, Denmark; June 3, 2009 – Genmab A/S (OMX: GEN) announced today its management will present at three investor conferences in June 2009.

June 10 – CEO Lisa N. Drakeman, Ph.D. will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York, NY at 11:00AM local time.

June 18 – CFO David Eatwell will present at the Jefferies 3rd Annual Healthcare Conference in New York, NY at 1:00PM local time.

June 23 – President, Research & Development Prof. Jan van de Winkel, Ph.D., will present at the Piper Jaffray European Healthcare Conference in London, UK at 10:30AM local time.

All three presentations will be available via live and archived webcast at www.genmab.com.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; HuMax-CD32b[™]; HuMax-TF[™]; HuMax-Her2[™]; HuMax-VEGF[™] and UniBody[®] are all trademarks of Genmab A/S. Arzerra[™] is a trademark of GlaxoSmithKline.

GENMAB TO PRESENT AT THREE JUNE INVESTOR CONFERENCES

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###